CYTO Profile
Altamira Therapeutics Ltd. is a biopharmaceutical company dedicated to developing innovative therapies for a range of unmet medical needs. Headquartered in Hamilton, Bermuda, and operating across Switzerland, the United States, Europe, and Australia, the company focuses on creating novel solutions in therapeutic areas with significant patient demand. Formerly known as Auris Medical Holding Ltd., Altamira Therapeutics underwent a rebranding in July 2021 to better reflect its evolving strategic vision.
Altamira’s portfolio includes Bentrio, a drug-free nasal spray designed to protect against airborne viruses and allergens. This product is aimed at providing a preventive measure for individuals exposed to environmental pathogens. The company is also advancing its RNA therapeutics platforms, notably OligoPhore and SemaPhore. These platforms, currently in preclinical development, are designed to enhance the delivery of oligonucleotides and mRNA therapies to extrahepatic targets, potentially expanding treatment options for various diseases.
In its clinical pipeline, Altamira is progressing several promising candidates. AM-125 is an intranasal treatment for vertigo, currently in Phase II clinical trials, which aims to offer a non-invasive solution for managing dizziness and balance disorders. Keyzilen, in Phase III trials, targets acute inner ear tinnitus, a condition characterized by persistent ringing or buzzing in the ears. Sonsuvi, another key asset in Phase III development, is being evaluated for its efficacy in treating acute inner ear hearing loss.
Altamira Therapeutics’ diverse portfolio and robust pipeline underscore its commitment to addressing significant medical challenges through innovative therapeutics. With a strategic focus on RNA-based technologies and a range of clinical-stage products, the company is well-positioned to make substantial contributions to the fields of otology and beyond, advancing the treatment landscape for conditions with high unmet needs.
|
